Market Research Logo

Male Hypogonadism - Pipeline Review, H2 2015

Male Hypogonadism - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Male Hypogonadism - Pipeline Review, H2 2015’, provides an overview of the Male Hypogonadism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Male Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Male Hypogonadism
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Male Hypogonadism and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Male Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Male Hypogonadism pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Male Hypogonadism
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Male Hypogonadism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Male Hypogonadism Overview
Therapeutics Development
Pipeline Products for Male Hypogonadism - Overview
Pipeline Products for Male Hypogonadism - Comparative Analysis
Male Hypogonadism - Therapeutics under Development by Companies
Male Hypogonadism - Therapeutics under Investigation by Universities/Institutes
Male Hypogonadism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Male Hypogonadism - Products under Development by Companies
Male Hypogonadism - Products under Investigation by Universities/Institutes
Male Hypogonadism - Companies Involved in Therapeutics Development
Antares Pharma, Inc.
BIOCAD
Clarus Therapeutics, Inc.
Diurnal Limited
EndoCeutics, Inc.
Ferring International Center S.A.
Forendo Pharma Limited
Lipocine Inc.
M et P Pharma AG
Merck & Co., Inc.
Mereo Biopharma Group Limited
Millennium Pharmaceuticals, Inc.
Monosol Rx, LLC
Pantarhei Bioscience BV
Repros Therapeutics Inc.
Male Hypogonadism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BGS-649 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
corifollitropin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
enclomiphene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fispemifene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
follitropin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kisspeptin-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LPCN-1111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MSS-722 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-448 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TBS-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Testavan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone enanthate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Male Hypogonadism - Recent Pipeline Updates
Male Hypogonadism - Dormant Projects
Male Hypogonadism - Discontinued Products
Male Hypogonadism - Product Development Milestones
Featured News & Press Releases
Nov 20, 2015: Antares Pharma Announces Poster Presentation at the Sexual Medicine Society Scientific Annual Meeting
Nov 12, 2015: Lipocine Announces PDUFA Goal Date for LPCN 1021 NDA
Nov 11, 2015: Lipocine Announces Presentation of LPCN 1021 Clinical Data at 21st Annual SMSNA Meeting
Nov 03, 2015: Antares Pharma Announces Enrollment Complete In Quickshot Supplemental Safety Study QST-15-005
Nov 02, 2015: Clarus Therapeutics Seeks Injunction Against the Marketing of Lipocine Oral Product for Testosterone Replacement Therapy
Oct 30, 2015: Antares Pharma Announces Update to Quickshot Testosterone Clinical Program
Oct 29, 2015: Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism
Oct 29, 2015: FDA Accepts for Filing Lipocine's New Drug Application for Its Oral Testosterone Replacement Product Candidate, LPCN 1021
Oct 28, 2015: Apricus Biosciences Completes Enrollment in Phase 2b Clinical Trial for Fispemifene in Men with Symptomatic Secondary Hypogonadism
Aug 31, 2015: Lipocine Submits New Drug Application to FDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Male Hypogonadism, H2 2015
Number of Products under Development for Male Hypogonadism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Male Hypogonadism - Pipeline by Antares Pharma, Inc., H2 2015
Male Hypogonadism - Pipeline by BIOCAD, H2 2015
Male Hypogonadism - Pipeline by Clarus Therapeutics, Inc., H2 2015
Male Hypogonadism - Pipeline by Diurnal Limited, H2 2015
Male Hypogonadism - Pipeline by EndoCeutics, Inc., H2 2015
Male Hypogonadism - Pipeline by Ferring International Center S.A., H2 2015
Male Hypogonadism - Pipeline by Forendo Pharma Limited, H2 2015
Male Hypogonadism - Pipeline by Lipocine Inc., H2 2015
Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2015
Male Hypogonadism - Pipeline by Merck & Co., Inc., H2 2015
Male Hypogonadism - Pipeline by Mereo Biopharma Group Limited, H2 2015
Male Hypogonadism - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Male Hypogonadism - Pipeline by Monosol Rx, LLC, H2 2015
Male Hypogonadism - Pipeline by Pantarhei Bioscience BV, H2 2015
Male Hypogonadism - Pipeline by Repros Therapeutics Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Male Hypogonadism Therapeutics - Recent Pipeline Updates, H2 2015
Male Hypogonadism - Dormant Projects, H2 2015
Male Hypogonadism - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Male Hypogonadism, H2 2015
Number of Products under Development for Male Hypogonadism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report